Market Cap (In USD)
531.87 Thousand
Revenue (In USD)
367.87 Thousand
Net Income (In USD)
-1259.26
Avg. Volume
-
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.0099-0.0099
- PE
- -
- EPS
- -
- Beta Value
- 1.776
- ISIN
- -
- CUSIP
- -
- CIK
- 1834645
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Hoyoung Huh M.D., Ph.D.
- Employee Count
- -
- Website
- https://peak-bio.com
- Ipo Date
- Details
- Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.
More Stocks
-
HAUTOHöegh Autoliners ASA
HAUTO
-
AQMSAqua Metals, Inc.
AQMS
-
HOM-UN
-
0N5Iadesso SE
0N5I
-
HNRC
-
BONDADABondada Engineering Limited
BONDADA
-
DSNG
-
603949Xuelong Group Co., Ltd.
603949